Compounders Research Compare

Crescent Biopharma, Inc.(CBIO)

Biotechnology · Waltham, MA

$13.84-0.10 (-0.72%)

Delayed quote: Oct 6, 2026, 2:55 PM EDT

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Waltham, MA

44 employees

crescentbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua T. Brumm

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T18:56:06.394Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:56:06.394Z.

Quote observation: 2026-10-06T18:55:11.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 514,072,130
TTM free cash flow · period ending 2026-06-30: -153,618,000

FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBIO Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

CBIO Competitors' Price/FCF Ratio

Crescent Biopharma, Inc.

Current

Market Cap

$514.07M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$508.74M

Price/FCF Ratio

1055.47

TTM Avg

838.04

3Y Avg

838.04

5Y Avg

838.04

Allogene Therapeutics, Inc.

Market Cap

$509.90M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$520.98M

Price/FCF Ratio

N/A

TTM Avg

0.26

3Y Avg

0.26

5Y Avg

0.26

Aclaris Therapeutics, Inc.

Market Cap

$522.51M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BlossomHill Therapeutics, Inc.

Market Cap

$517.94M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tactile Systems Technology, Inc.

Market Cap

$500.75M

Price/FCF Ratio

18.74

TTM Avg

15.64

3Y Avg

12.14

5Y Avg

236.08

Immix Biopharma, Inc.

Market Cap

$525.52M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Oculis Holding AG

Market Cap

$495.66M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nuvectis Pharma, Inc.

Market Cap

$536.04M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Crescent Biopharma, Inc. (CBIO)	$514.07M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$508.74M	1055.47	838.04	838.04	838.04
Allogene Therapeutics, Inc. (ALLO)vs ›	$509.90M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$520.98M	N/A	0.26	0.26	0.26
Aclaris Therapeutics, Inc. (ACRS)vs ›	$522.51M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$517.94M	N/A	N/A	N/A	N/A
Tactile Systems Technology, Inc. (TCMD)vs ›	$500.75M	18.74	15.64	12.14	236.08
Immix Biopharma, Inc. (IMMX)vs ›	$525.52M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$495.66M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$536.04M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics